Eli Lilly Acquires OLX75016 from OliX Pharmaceuticals for Metabolic-Associated Steatohepatitis
Shots:
- OliX & Eli Lilly have entered into a global license agreement to develop & commercialize OliX’s OLX75016 for metabolic-associated steatohepatitis (MASH) as well as other cardiometabolic indications
- As per the agreement, Eli Lilly will make an initial payment of ~$630M to OliX for completing the ongoing P-I trial of OLX75016 in Australia, after which Lilly will handle further development
- In preclinical models, OLX75016 (RNAi therapeutic) has shown efficacy againstefficacy against MASH with liver fibrosis & other cardiometabolic diseases
Ref: Businesswire | Image: OliX & Eli Lilly
Related News:- Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
